Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bioAffinity Technologies, Inc. - Warrant (NQ:BIAFW)

0.6523 +0.1293 (+24.72%)
Streaming Delayed Price Updated: 12:48 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about bioAffinity Technologies, Inc. - Warrant

< Previous 1 2 3 Next >
bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of $4.8 Million Public Offering
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules
From bioAffinity Technologies, Inc.
Via Business Wire
U.S. Medicine Magazine Spotlights CyPath® Lung as Promising Tool to Improve Lung Cancer Detection in Veterans, Lower Costs to the VA
From bioAffinity Technologies
Via Business Wire
bioAffinity Technologies Appoints New Members to Board of Directors
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Second Quarter 2025 Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Neuroendocrine Tumor Missed by Other Diagnostic Tools
From bioAffinity Technologies, Inc.
Via Business Wire
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company’s Noninvasive Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Notification of China Patent Award for Company’s Noninvasive Lung Cancer Diagnostic
From bioAffinity Technologies, Inc.
Via Business Wire
Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas’ Leadership Board
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports First Quarter 2025 Results
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Closing of $3.25 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Announces Pricing of $3.25 Million Offering
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost
From bioAffinity Technologies, Inc.
Via Business Wire
bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024
From bioAffinity Technologies, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.